Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Clinical Trials
•
Pediatric Oncology
•
Oncology
What are the main barriers you encounter in enrolling pediatric oncology patients on clinical trials?
Related Questions
Which oral chemotherapy regimen do you use in relapsed fusion positive rhabdomyosarcoma?
How do you approach revaccination after chemotherapy, and what labs (if any) do you use to assess immune reconstitution?
What is your approach to patients/parents seeking alternative or complementary treatment in pediatric oncology patients?
When do you consider altering treatment for a patient with metastatic osteosarcoma who showed poor response to upfront therapy with MAP (doxorubicin, cisplatin, methotrexate) chemotherapy?
How do you incorporate psychological care into the surveillance and treatment of a pediatric patient found to have a cancer predisposition syndrome?
What is your typical surveillance imaging for a pediatric patient with history of treated sarcoma off therapy?
Do you routinely use thrombopoietin receptor agonists (like romiplostim) to address chemotherapy-induced thrombocytopenia in solid tumor pediatric oncology patients?
What workup do you complete for a teenage patient presenting with an incidentally discovered adrenal mass?
How do you approach adjuvant therapy for resected Stage I Ewing sarcoma of the kidney, and what chemotherapy regimen and cycle duration do you recommend?
For which pediatric oncology patients do you start bacterial prophylaxis, inpatient or outpatient, and what is your antibiotic of choice?
